COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-27
DOI
10.1186/s13045-021-01046-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration
- (2020) Giovanni Damiani et al. Dermatologic Therapy
- Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
- (2020) Ling Ni et al. IMMUNITY
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Development of an inactivated vaccine candidate for SARS-CoV-2
- (2020) Qiang Gao et al. SCIENCE
- DNA vaccine protection against SARS-CoV-2 in rhesus macaques
- (2020) Jingyou Yu et al. SCIENCE
- Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers
- (2020) Jia Luo et al. Cancer Discovery
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
- (2020) Vikas Mehta et al. Cancer Discovery
- How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies
- (2020) Joshua A. Hill et al. BLOOD
- Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
- (2020) Therse Björkin Joona et al. BREAST CANCER RESEARCH AND TREATMENT
- Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
- (2020) Hui Wang et al. CELL
- A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
- (2020) Ahmed O. Hassan et al. CELL
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- (2020) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
- (2020) Wei Deng et al. SCIENCE
- Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
- (2020) Donna R Rivera et al. Cancer Discovery
- On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
- (2020) Thilo Gambichler et al. Journal for ImmunoTherapy of Cancer
- mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
- (2020) Gal Cafri et al. JOURNAL OF CLINICAL INVESTIGATION
- Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
- (2020) Julio García-Suárez et al. Journal of Hematology & Oncology
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
- (2020) Ugur Sahin et al. NATURE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
- (2020) Jesús Loarce-Martos et al. RHEUMATOLOGY INTERNATIONAL
- A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
- (2020) Shipo Wu et al. Nature Communications
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
- (2020) Anup Agarwal et al. BMJ-British Medical Journal
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Frontiers in the COVID-19 vaccines development
- (2020) Ehtisham Ul Haq et al. Experimental Hematology & Oncology
- Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
- (2020) Lauren B. Rodda et al. CELL
- COVID-19-neutralizing antibodies predict disease severity and survival
- (2020) Wilfredo F. Garcia-Beltran et al. CELL
- Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
- (2020) Yuezhou Chen et al. CELL
- Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients
- (2020) Gaili Chen et al. Journal of Hematology & Oncology
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
- (2020) Antoni Ribas et al. Cancer Discovery
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
- (2020) Sara E. Oliver et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection
- (2020) QuanQiu Wang et al. JAMA Oncology
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- (2019) Christine Ménétrier-Caux et al. Journal for ImmunoTherapy of Cancer
- Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
- (2019) Malgorzata Mikulska et al. LANCET INFECTIOUS DISEASES
- mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
- (2019) Robert A. Feldman et al. VACCINE
- A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
- (2019) Liu Vaccines
- Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
- (2019) Kristine A. Frerichs et al. HAEMATOLOGICA
- Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor
- (2019) Bhumsuk Keam et al. CLINICAL INFECTIOUS DISEASES
- Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
- (2018) C T Rieger et al. ANNALS OF ONCOLOGY
- Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
- (2018) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Ibrutinib may impair serological responses to influenza vaccination
- (2017) Abby P. Douglas et al. HAEMATOLOGICA
- Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer
- (2017) Anna E. Kersh et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ibrutinib may impair serological responses to influenza vaccination
- (2017) Abby P. Douglas et al. HAEMATOLOGICA
- Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
- (2016) V. G. Bhoj et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles
- (2016) Bhumsuk Keam et al. CANCER
- Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
- (2016) Clare Sun et al. JAMA Oncology
- The response to vaccination against influenza A(H1N1) 2009, seasonal influenza andStreptococcus pneumoniaein adult outpatients with ongoing treatment for cancer with and without rituximab
- (2014) Åke Berglund et al. ACTA ONCOLOGICA
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
- (2013) H. de Lavallade et al. BLOOD
- The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
- (2013) I. Nazi et al. BLOOD
- 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
- (2013) Lorry G. Rubin et al. CLINICAL INFECTIOUS DISEASES
- Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours
- (2013) M.L. Wumkes et al. VACCINE
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
- (2012) Chien-Te Tseng et al. PLoS One
- Response to influenza virus vaccination during chemotherapy in patients with breast cancer
- (2011) A. Meerveld-Eggink et al. ANNALS OF ONCOLOGY
- Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination
- (2011) S. F. Mulder et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started